195 related articles for article (PubMed ID: 27421271)
1. Optimal screening interval for men with low baseline prostate-specific antigen levels (≤1.0 ng/mL) in a prostate cancer screening program.
Urata S; Kitagawa Y; Matsuyama S; Naito R; Yasuda K; Mizokami A; Namiki M
World J Urol; 2017 Apr; 35(4):579-586. PubMed ID: 27421271
[TBL] [Abstract][Full Text] [Related]
2. Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1-10.0 ng/ml at population screening.
Kitagawa Y; Ueno S; Izumi K; Kadono Y; Konaka H; Mizokami A; Namiki M
J Cancer Res Clin Oncol; 2014 Jan; 140(1):53-9. PubMed ID: 24165867
[TBL] [Abstract][Full Text] [Related]
3. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
[TBL] [Abstract][Full Text] [Related]
4. Cumulative risk of developing prostate cancer in men with low (≤ 2.0 ng/mL) prostate-specific antigen levels: a population-based screening cohort study in Japan.
Sawada K; Kitagawa Y; Ito K; Takeda Y; Mizokami A; Namiki M
Int J Urol; 2014 Jun; 21(6):560-5. PubMed ID: 24372775
[TBL] [Abstract][Full Text] [Related]
5. Impact of PSA levels on second-round screening for the development of prostate cancer in men with low baseline PSA levels (≤2.0 mg/ml).
Kitagawa Y; Sawada K; Urata S; Izumi K; Ueno S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2014 Nov; 34(11):6739-46. PubMed ID: 25368284
[TBL] [Abstract][Full Text] [Related]
6. Reduced cancer-specific survival of low prostate-specific antigen in high-grade prostate cancer: A population-based retrospective cohort study.
Song P; Yang B; Peng Z; Zhou J; Ren Z; Fang K; Yang L; Wang L; Dong Q
Int J Surg; 2020 Apr; 76():64-68. PubMed ID: 32109649
[TBL] [Abstract][Full Text] [Related]
7. Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer.
Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
Int J Cancer; 2004 Apr; 109(3):455-60. PubMed ID: 14961587
[TBL] [Abstract][Full Text] [Related]
8. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A
BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial.
Frånlund M; Arnsrud Godtman R; Carlsson SV; Lilja H; Månsson M; Stranne J; Hugosson J
Scand J Urol; 2018 Aug; 52(4):256-262. PubMed ID: 30241447
[TBL] [Abstract][Full Text] [Related]
10. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
Prostate; 2003 Sep; 57(1):8-13. PubMed ID: 12886518
[TBL] [Abstract][Full Text] [Related]
11. A novel screening strategy for clinically significant prostate cancer in elderly men over 75 years of age.
Iwamoto H; Izumi K; Kadomoto S; Makino T; Naito R; Yaegashi H; Shigehara K; Kadono Y; Mizokami A
Asian J Androl; 2021; 23(1):36-40. PubMed ID: 32769233
[TBL] [Abstract][Full Text] [Related]
12. The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study.
Palsdottir T; Nordstrom T; Karlsson A; Grönberg H; Clements M; Eklund M
BMJ Open; 2019 Mar; 9(3):e027958. PubMed ID: 30928965
[TBL] [Abstract][Full Text] [Related]
13. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
Stattin P; Vickers AJ; Sjoberg DD; Johansson R; Granfors T; Johansson M; Pettersson K; Scardino PT; Hallmans G; Lilja H
Eur Urol; 2015 Aug; 68(2):207-13. PubMed ID: 25682340
[TBL] [Abstract][Full Text] [Related]
14. Cumulative probability of prostate cancer detection using the international prostate symptom score in a prostate-specific antigen-based population screening program in Japan.
Kitagawa Y; Urata S; Narimoto K; Nakagawa T; Izumi K; Kadono Y; Konaka H; Mizokami A; Namiki M
Asian Pac J Cancer Prev; 2014; 15(17):7079-83. PubMed ID: 25227794
[TBL] [Abstract][Full Text] [Related]
15. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer.
Mahal BA; Aizer AA; Efstathiou JA; Nguyen PL
Cancer; 2016 Jan; 122(1):78-83. PubMed ID: 26371600
[TBL] [Abstract][Full Text] [Related]
16. Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Kovac E; Carlsson SV; Lilja H; Hugosson J; Kattan MW; Holmberg E; Stephenson AJ
JAMA Netw Open; 2020 Jan; 3(1):e1919284. PubMed ID: 31940039
[TBL] [Abstract][Full Text] [Related]
17. Optimal prostate-specific antigen screening interval for prostate cancer.
Kobayashi D; Takahashi O; Fukui T; Glasziou PP
Ann Oncol; 2012 May; 23(5):1250-1253. PubMed ID: 21948815
[TBL] [Abstract][Full Text] [Related]
18. The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels.
Izumi K; Ikeda H; Maolake A; Machioka K; Nohara T; Narimoto K; Ueno S; Kadono Y; Kitagawa Y; Konaka H; Mizokami A; Namiki M
Prostate; 2015 Jul; 75(10):1034-42. PubMed ID: 25753899
[TBL] [Abstract][Full Text] [Related]
19. The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0 ng/ml or less.
Ito K; Yamamoto T; Suzuki K; Kurokawa K; Yamanaka H
J Urol; 2004 Feb; 171(2 Pt 1):656-60. PubMed ID: 14713780
[TBL] [Abstract][Full Text] [Related]
20. Age-specific reference range of prostate-specific antigen and prostate cancer detection in population-based screening cohort in Japan: verification of Japanese Urological Association Guideline for prostate cancer.
Kitagawa Y; Izumi K; Sawada K; Mizokami A; Nakashima K; Koshida K; Nakashima T; Miyazaki K; Namiki M
Int J Urol; 2014 Nov; 21(11):1120-5. PubMed ID: 24931145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
